Study M768
Study name | Shen DD 2021 |
Title | Clinical serum metabolomics study on fluoxetine hydrochloride for depression |
Overall design | The aim of this study was to evaluate the antidepressant effect of fluoxetine hydrochloride by metabolomics, so that to find out its specific biomarkers and related metabolic characteristics of depression in the treatment of depression and analyze the intervention mechanism of fluoxetine hydrochloride in depression. Fifteen depression patients (depression group) and twenty healthy volunteers (control group) were recruited in clinical. Depression patients take fluoxetine hydrochloride orally once a day and one tablet each time for 8 weeks. Ultraperformance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) was used to analyze serum metabolites of depression patients pretherapy and post-treatment and compared with healthy people. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV diagnosed depression, HAMD-24 score between 20 and 34 |
Sample size | 35 |
Tissue | Peripheral; Blood; Serum; |
Platform | MS-based; LC-MS: UPLC-Q-TOF/MS system (Waters); |
PMID | |
DOI | |
Citation | Shen D, Zhao H, Gao S, et al. Clinical serum metabolomics study on fluoxetine hydrochloride for depression. Neurosci Lett. 2021 Feb 16;746:135585. |
Metabolite | Citric acid; L-Tyrosine; Phenylpyruvic acid; D-Glucose; Oxoglutaric acid; LysoPC(20:1); Acetyl-CoA; Coenzyme A; ADP; LysoPC(O-18:0); N-Acetylneuraminic acid; |
